Corporate News tagged:

Stem cells (2)

REPROCELL Corporate News

Notice of formation of contract with FANCL Corp. for human iPS cell-derived model cell development

16 November 2016

A Joint Development with the National Cancer Center Information Regarding the Sale of “ReproHP Medium,” a Culture Fluid for Human Primary Liver Cells with High Levels of Functionality

16 November 2015

Notice of Passage of Examination for United States Patent Application Concerning Amplification Method of Hematopoietic Stem Cells

04 November 2015

The REPROCELL Group announces publication of a paper on its state-of-the-art RNA Reprogramming technology in Human Gene Therapy, an international journal

14 October 2015

Joint Announcement with Ajinomoto Co., Inc. Notification of the Beginning of Sales of StemFIT® AK02N High-Performance Culture Solution for Regenerative Medicine Use Human iPS Cells

24 September 2015

REPROCELL concludes license agreement with Keio University for the exclusive sale of myocardial cells derived from disease-type (long QT syndrome, a congenital heart disease) iPS cells

08 September 2015

Announcement: New High Performance Cryopreservation Solution – ReproCryo DMSO Free

26 August 2015

Announcement of Award for Prototype Development of Large-Scale Production on Human-iPSC derived Cardiomyocytes

14 August 2015

Diseased neurons derived from iPS cells of Alzheimer’s disease patients Initiation of sales of “ReproNeuro AD-patient”

29 July 2015

Announcement: sales commencement of “ReproNeuro MQ Medium”, a cell culture kit which enables the creation of high-functioning nerve cells derived from human iPS cells

21 July 2015

Announcement of Award for Prototype Development of a Liver Cell Kit

01 July 2015

Stemgent, a REPROCELL Group Company Announces a New High Performance Self-replicative RNA Reprogramming Kit

30 June 2015

REPROCELL Concludes the License Agreement with Keio University for the Exclusive Sale of Disease (Hypertrophic Cardiomyopathy) Type Myocardial Cells Derived from iPS Cells

04 June 2015

REPROCELL Acquires the iPS Cell Business Unit of Stemgent, Inc. (USA)

09 September 2014
 Previous 1 2

Stem cell and drug discovery scientists around the world are using REPROCELL’s services and products in their preclinical and clinical research.

 About REPROCELL

Subscribe to receive updates

Corporate news by tag

  1. 3D cell culture
  2. Clinical capabilities
  3. Drug discovery
  4. Genomic services
  5. Human tissue samples
  6. Human tissue testing
  7. Life sciences
  8. Precision medicine
  9. Product Catalog
  10. Stem cells

 Corporate news archive